5,935 research outputs found
O curso de licenciatura em educação física da Universidade Federal de Santa Catarina: suas concepções de ensino e de educação física
No full textDissertação (mestrado) - Universidade Federal de Santa Maria. Centro de Educação Fisica e Desporto
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD
No full textLABA+LAMA and LABA+ICS combinations are key pharmacological approaches to the treatment of COPD. However, both combination types can induce adverse events (AEs). Areas covered: Current literature on LABA+LAMA and LABA+ICS combinations has been reviewed with a specific focus on their safety profile in the treatment of COPD. Expert opinion: Several meta-analyses have compared the pooled safety data from randomized clinical trials (RCTs) of LABA+LAMA combinations with LABA+ICS combinations. LABA+LAMA caused significantly less AEs and SAEs. However, this evidence in real life is less solid because of the lack of appropriate studies. A statistically significant reduction in the risk for pneumonia with LABA+LAMA compared with LABA+ICS has been repeatedly documented by various meta-analyses. The meta-analytic signal indicates that an equal number of patients would die or have cardiac SAEs on LABA+LAMA or LABA+ICS, and in an observational, real-life study the LABA+LAMA combination had similar or lower risk of these events in comparison to LABA+ICS. Nonetheless, since RCTs are conducted under widely varying conditions and, consequently, AE rates of a drug observed in a RCT cannot be directly compared with rates in the RCTs of another drug and may not reflect the rates observed in practice, we need more specific data
Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple therapy in COPD
No full textInhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination commonly prescribed to treat chronic obstructive pulmonary disease (COPD). Therefore, we performed a meta-analysis on the impact of adding a long-acting muscarinic receptor antagonist (LAMA) to ICS/LABA combination in COPD
PENGARUH GIRO WADIAH, TABUNGAN WADIAH DAN TABUNGAN MUDHARABAH TERHADAP LABA PT. BANK SYARIAH MANDIRI PERIODE 2012-2019
No full textABSTRAK
Skripsi dengan judul “Pengaruh Giro Wadiah, Tabungan Wadiah dan
Tabungan Mudharabah Terhadap Laba PT. Bank Syariah Mandiri Periode 2012-
2019” ini ditulis oleh Siti Maria Ulfa, NIM. 12401173019, Fakultas Ekonomi dan
Bisnis Islam, Jurusan Perbankan Syariah, Institut Agama Islam Negeri
Tulungagung dibimbing oleh Dr. H. Ahmad Muhtadi Anshor, M. Ag.
Penelitian ini dilatarbelakangi oleh laba Bank Syariah Mandiri yang
mengalami kenaikan dan penurunan, kondisi tersebut menjadi perhatian pihak
manajemen bank mengingat dalam mengukur keberhasilan suatu kinerja
perusahaan, laba menjadi salah satu indikator penting. Semakin meningkat laba
yang didapatkan maka kinerja perbankan semakin baik. Jika laba yang didapatkan
meningkat maka masyarakat juga banyak yang menyimpan dananya. Karena
dengan begitu maka masyarakat akan percaya pada perbankan tersebut. Pada
penelitian ini menggunakan giro wadiah, tabungan wadiah dan tabungan
mudharabah sebagai faktor untuk mengetahui seberapa besar pengaruhnya terhadap
laba Bank Syariah Mandiri.
Rumusan masalah dalam penelitian ini adalah (1) Apakah giro wadiah
berpengaruh terhadap laba pada PT. Bank Syariah Mandiri Periode 2012-2019?, (2)
Apakah tabungan wadiah berpengaruh terhadap laba pada PT. Bank Syariah
Mandiri Periode 2012-2019?, (3) Apakah tabungan mudharabah berpengaruh
terhadap laba pada PT. Bank Syariah Mandiri Periode 2012-2019?. Adapun tujuan
dari penelitian ini adalah untuk mengetahui seberapa besar pengaruh giro wadiah,
tabungan wadiah dan tabungan mudharabah terhadap laba PT. Bank Syariah
Mandiri Periode 2012-2019.
Penelitian ini menggunakan pendekatan kuantitatif dengan jenis analisis
asosiatif. Data yang digunakan adalah data sekunder yang diperoleh dari laporan
keuangan triwulan Bank Syariah Mandiri periode 2012-2019. Teknik analisis data
yang digunakan adalah analisis regresi linier berganda yang meliputi uji normalitas
data, uji asumsi klasik, uji regresi linier berganda, uji hipotesis dan uji koefisien
determinasi.
Hasil penelitian menunjukkan bahwa (1) Giro wadiah tidak berpengaruh positif
dan tidak signifikan terhadap laba PT. Bank Syariah Mandiri Periode 2012-2019,
(2) Tabungan wadiah berpengaruh negatif dan signifikan terhadap laba PT. Bank
Syariah Mandiri Periode 2012-2019, (3) Tabungan mudharabah berpengaruh
positif dan signifikan terhadap laba PT. Bank Syariah Mandiri Periode 2012-2019.
Kata Kunci : Giro Wadiah, Laba, Tabungan Mudharabah, dan Tabungan Wadiah
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD
No full textThe wide availability of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) fixed-dose combinations (FDCs) in the absence of head-to-head comparative pragmatic trials makes it difficult to choose which combination should be used. Therefore, we carried out a systematic review with meta-analysis that incorporated the data from trials lasting at least 3 months to evaluate the effectiveness of LAMA/LABA FDCs for COPD treatment
Imagens de Otto Maria Carpeaux: esboço de biografia
No full textTese (doutorado) - Universidade Federal de Santa Catarina, Centro de Filosofia e Ciências Humanas, Programa de Pós-Graduação em História, Florianópolis, 2015.Este esboço de biografia procura citar algumas imagens de Otto Maria Carpeaux: construções biográficas de naturezas múltiplas, elaboradas em contextos, por atores e sob condições igualmente díspares. Está constituído a partir de uma visão crítica da História, o que permite que ?outras imagens?, fragmentárias e não monumentais, também tenham espaço. Em diálogo com o princípio da montagem, este esboço apresenta-se em duas partes. Na primeira, Imagens possíveis, estão citadas as imagens elaboradas em vida e post mortem acerca do austríaco-brasileiro que nasceu em Viena em 1900, se exilou no Brasil em 1939 e morreu no Rio de Janeiro, em 1978. Na segunda, Montagens possíveis, apresentam-se duas possibilidades de exercício biográfico: pela leitura alegórica do documentário O velho e o Novo (Otto Maria Carpeaux), entendido como instrumento de intervenção no contexto ditatorial brasileiro e de uma reelaboração biográfica concernentes às suas experiências europeias; e pelo Caderno de imagens críticas, registro dos encontros em Carpeaux pelo meio de imagens críticas produzidas a partir da cesura do presente.Abstract : This biographical sketch attempts to quote some images of Otto Maria Carpeaux: various types of biographical constructions, carried out in different contexts by disparate authors under conditions just as distinct. It stems from a critical view of history, allowing for ?other images? fragmented and non-monumental ? to share the space.In dialogue with the montage principle, this sketch has two parts. The first, Possible Images, quotes the images produced during and after the life of the Austrian-Brazilian, who was born in Vienna in 1900, went to Brazil in exile in 1939 and died in Rio de Janeiro in 1978. The second part, Possible Montages, presents two possibilities of a biographical exercise: through the allegorical reading of documentary O Velho e o Novo (Otto Maria Carpeaux), understood as an instrument of intervention in the Brazilian dictatorship context and as a biographical retelling of the author?s European experiences; and through my Scrapbook of Critical Images, a record of the encounters in Carpeaux through critical images produced from the caesura of the present
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
No full textMario Cazzola,1 Andrea Segreti,1 Maria Gabriella Matera2 1Department of System Medicine, University of Rome 'Tor Vergata', Rome, Italy; 2Department of Experimental Medicine, Second University, Naples, Italy Abstract: An increasing body of evidence suggests that the long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combination appears to play an important role in maximizing bronchodilation, with studies to date indicating that combining different classes of bronchodilators may result in significantly greater improvements in lung function compared to the use of a single drug, and that these combinations are well tolerated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). An inhaled, fixed-dose combination of two 24-hour bronchodilators, the LAMA umeclidinium and the LABA vilanterol, is under development as a once-daily treatment for COPD. The efficacy of both mono-components has already been demonstrated. The information currently available suggests that umeclidinium/vilanterol is an effective once-daily dual bronchodilator fixed-dose combination in the treatment of COPD. However, it remains to be seen if it compares favorably with current therapies. Moreover, the question remains whether umeclidinium/vilanterol fixed-dose combination, which significantly improves FEV1, is also associated with improvements in other outcome measures that are important to COPD patients. Keywords: muscarinic antagonist, dual bronchodilation, COP
Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
No full textFluticasone furoate/vilanterol (FF/VI) is a novel inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) fixed dose combination that, by simplifying the dosing schedule, allows, for the first time in a member of the ICS/LABA class, a shift from twice-daily to once-daily treatment. FF/VI is delivered via a novel, single-step activation, multi-dose dry powder inhaler for oral inhalation, ElliptaTM. Regrettably, there are no head-to-head trials that have shown superiority in the safety or efficacy of FF versus other ICSs, but evidence shows that VI has a quicker onset of effect versus salmeterol. However, the clinical utility of this effect in a maintenance medication is still questionable. Furthermore, benefits of FF/VI over twice-daily ICS/LABA comparator have not been shown yet and, in addition, its adverse event profile is generally consistent with the known class effects of an ICS/LABA fixed dose combination. In particular, there is an increase in the risk of pneumonia among patients treated with FF/VI relative to VI, mainly among those who benefit most from FF/VI. Nevertheless, the interesting pharmacological profiles of both FF and VI, the possibility that FF/VI can be administered once-daily, and the attractive characteristics of ElliptaTM are important features that could help FF/VI to be a successful combination in the treatment of chronic obstructive pulmonary diseas
Ippolito Rosellini, l'Egitto, l'Egittologia /Ippolito Rosellini, Egypt and Egyptology
No full textThe paper focuses on Ippolito Rosellini, co-director with J.F. Champollion of the Franco-Tuscan Expedition to Egypt (1828-29) and first Professor of Egyptology in Europe, at the University of Pisa. His important contribution to the formative phase of the new-born Egyptology is highlighted through the study of his unpublished manuscripts and some drawings of the Expedition in the Biblioteca Universitaria of Pisa. These documents were studied, digitized and put on the web in the framework of a specific project, directed by the author, “Progetto Rosellini”. The volume including this paper, it too edited by M. Betrò, is the catalogue of the homonymous exhibition organized by the author in the Egyptian Museum of Cairo in 2010. The international exhibition exposed for the first time in Egypt about one hundred drawings and manuscripts among the most important and beautiful from Ippolito Rosellini and the Tuscan Expedition Archive
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease
No full textCombining a long-acting β(2)-agonist (LABA) and a long-acting antimuscarinic agent (LAMA) is potentially a good pharmacological approach to improve clinical results in stable moderate chronic obstructive pulmonary disease (COPD) patients when symptoms are not adequately controlled with tiotropium monotherapy. Consequently, there is a strong interest in developing a LABA/LAMA fixed-dose combination therapy in an attempt to simplify the treatment
- …
